January 2024
Inhalation 1-2-3 A brief update from Inhaltion Magazine.
 
Interek
 
perspective

Exploring low moisture content capsules for dry powder inhalers
imageInnovative capsules with reduced moisture content can offer promising possibilities for developing dry powder inhaler (DPI) products containing moisture-sensitive active pharmaceutical ingredients (APIs). However, reducing capsule moisture can lead to increased brittleness and potential defects during manufacturing and clinical use. Understanding the mechanical properties of these capsules is crucial to assess their practical viability.

In a recent study, researchers utilized puncture and compression tests to evaluate extra-dried capsules compared to conventional capsules with higher moisture content. Surprisingly, the study revealed that the lower moisture content did not significantly impact the capsules' mechanical performance. This finding paves the way for further exploration of these low moisture content capsules in aerosolizing dry powder formulations for DPIs, offering new possibilities for delivering sensitive APIs effectively.

Qualicaps® Europe
Spain: +34 91 663 08 00
qualicaps.com
 
Copley
 
in focus

imageExploring the robustness of the pharmacopeial methods for testing dry powder inhalers (DPIs); Part 2: Aerodynamic particle size distribution (APSD)
The first article in this series explored the robustness of the pharmacopeial methodology for the determination of delivered dose uniformity (DDU) for orally inhaled products to bias in volumetric flow rate setting from variations in ambient pressure. In this second article, the authors extend the analysis to evaluate how the determination of the second performance-related critical quality attribute, aerodynamic particle size distribution (APSD), might be affected by similar ambient pressure changes, as well as other factors.

Findings from this analysis of the underlying physical processes involved with the determination of APSD of the aerosol emitted from a passive DPI following methodology advocated in the pharmacopeial compendia again add support for the robustness of these methods. However, the authors have identified several facts for readers to consider in performance testing of these orally inhaled products.
 
Qualicaps
 
feature

imageAntibody-loaded polymeric nanoparticles as a promising strategy for inhalable lung cancer treatment
This article discusses development of polymeric nanoparticles intended to obtain optimal features for loading therapeutic antibodies and be formulated into dry powders for inhalable lung cancer treatment. This may reduce serious side effects and toxicity and support therapeutic adherence, effectiveness and safety. The article also discusses dry powder formulation with respect to particle deposition profile and the spray-drying process.

Pulmonary delivery of dry powders can enable targeted cancer therapy to reach the lung.
In turn, therapeutic antibodies used as lung anti-cancer therapy could be delivered by inhalation. Antibody nanoencapsulation may play a key role in antibody stability and maintenance of bioactivity. An additional process of microencapsulation through spray drying can provide nanoparticles with characteristics to support lung delivery. Further studies are necessary to evaluate antibody structure and bioactivity preservation after drying, as well as interactions with the microparticle matrix.
 
Start or renew your free subscription to Inhalation
 
image

image
Click for information on the following industry event:
  • Respiratory Drug Delivery 2024
Please visit Inhalation's website to see contact information for multiple industry organizations, many of which present conferences, workshops and other educational events:

inhalationmag.com/industry-organizations
Start or renew your free subscription to Inhalation
 
Questions about Inhalation,
contact Vicki L. Schuman, Editor and Publisher at vschuman@inhalationmag.com.
w: inhalationmag.com • e: inquiries@inhalationmag.com

 
This email was sent to you from inhnews@cscpublish.com. To ensure delivery of these emails in your inbox,
please add both cscpublish.com and inhalationmag.com to your safe senders list.
Privacy Policy • Unsubscribe

Inhalation Magazine • P.O. Box 27092 • Minneapolis, MN 55427 US

© Whipsnade and Loophole LLC 2024